Purpose: This research study was conducted to evaluate the impact of (Ga)-tagged prostatic-specific membrane antigen (Ga-PSMA) positron emission tomography and computed tomography (PET-CT), compare its role with conventional radiology in early staging of high-risk prostate cancer, and calculate the PSMA score evaluating its usefulness in Ga-PSMA PET-CT reporting in our patient population.
Material And Methods: Ga-PSMA PET-CT of 65 high-risk cases of prostate cancer was performed for staging purpo-ses. Any change in disease stage was noted after Ga-PSMA PET-CT findings and PSMA score leading to a change in the management plan.
Results: Change in disease stage post-PSMA imaging was seen in 39% cases, high PSMA score (03) was noted in > 80% of upstaged cases, while low score (0) and (1) was seen in 65% and 35% down-staged individuals, respectively. Change in therapeutic decision-making was observed in 32% (21) of patients.
Conclusions: Ga-PSMA PET-CT scans have a significant influence on the planned clinical management of high-risk prostate cancer patients; hence, they can be utilized as a replacement for radiological imaging tools, particularly in the detection of pelvic nodal and distant metastatic disease. PSMA score can be considered as an effective tool in standardized reporting of Ga-PSMA imaging.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10415808 | PMC |
| http://dx.doi.org/10.5114/pjr.2023.130196 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Can PSMA PET detect intratumour heterogeneity in histological PSMA expression of primary prostate cancer? Analysis of [Ga]Ga-PSMA-11 and [F]PSMA-1007.
Eur J Nucl Med Mol Imaging
January 2025
Department of Radiation Oncology, University Medical Centre Freiburg, Robert-Koch Straße 3, 79106, Freiburg, Germany.
Purpose: Prostate-specific membrane-antigen positron emission tomography (PSMA PET) is a promising candidate for non-invasive characterization of prostate cancer (PCa). This study evaluated whether PET with tracers [Ga]Ga-PSMA-11 or [F]PSMA-1007 is capable to depict intratumour heterogeneity of histological PSMA expression.
Methods: Thirty-five patients with biopsy-proven primary PCa without evidence of metastatic disease nor prior interventions were prospectively enrolled.
Gastric Adenocarcinoma Incidentally Detected by PET/CT with PSMA Ligands.
Diagnostics (Basel)
January 2025
Division of Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.
Here, we describe the case of a 74-year-old male patient with a high-risk prostate carcinoma who underwent positron-emission tomography/computed tomography (PET/CT) with [Ga]Ga-prostate-specific membrane antigen ([Ga]Ga-PSMA-11) for staging. [Ga]Ga-PSMA-11 PET/CT detected an extensive area of increased tracer uptake at the prostatic level, involving both lobes. Additionally, a rounded lesion approximately 4 cm in diameter was identified in the celiac region adjacent to the stomach, exhibiting moderate tracer uptake.
View Article and Find Full Text PDFStaging of prostate Cancer with ultra-fast PSMA-PET scans enhanced by AI.
Eur J Nucl Med Mol Imaging
January 2025
Department of Nuclear Medicine and German Cancer Consortium (DKTK), University Hospital Essen, University of Duisburg-Essen, Hufelandstraße 55, Essen, 45147, Germany.
Purpose: PSMA-PET is a reference standard examination for patients with prostate cancer, but even using recently introduced digital PET detectors image acquisition with standard field-of-view scanners is still in the range of 20 min. This may cause limited access to examination slots because of the growing demand for PSMA-PET. Ultra-fast PSMA-PET may enhance throughput but comes at the cost of poor image quality.
View Article and Find Full Text PDFEvaluating the prognostic value of radiomics and clinical features in metastatic prostate cancer using [Ga]Ga-PSMA-11 PET/CT.
Phys Eng Sci Med
January 2025
School of Physics, Mathematics and Computing, University of Western Australia, Crawley, WA, Australia.
Prostate cancer is a significant global health issue due to its high incidence and poor outcomes in metastatic disease. This study aims to develop models predicting overall survival for patients with metastatic biochemically recurrent prostate cancer, potentially helping to identify high-risk patients and enabling more tailored treatment options. A multi-centre cohort of 180 such patients underwent [Ga]Ga-PSMA-11 PET/CT scans, with lesions semi-automatically segmented and radiomic features extracted from lesions.
View Article and Find Full Text PDFDiffuse Peritoneal Carcinomatosis of Prostate Cancer Unveiled by [89Zr]Zr-PSMA-617 PET/CT.
Clin Nucl Med
February 2025
From the Department of Nuclear Medicine, Saarland University, Homburg, Germany.
We report an interesting case of a 64-year-old man with a history of radical prostatectomy for prostate cancer. The patient presented with steady increasing prostate-specific antigen levels, but with negative findings on previous multiple conventional prostate-specific membrane antigen (PSMA) PET/CT (with [68Ga]Ga-PSMA-11) and [18F]FDG PET/CT. A recently introduced PSMA tracer using long-lived 89Zr (half-life 3.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!